Moleculin Biotech’s Growth Potential Highlighted by Phase 3 MIRACLE Trial and Strategic Advancements

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) yesterday and set a price target of $4.00.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight Moleculin Biotech’s potential for growth and success. The company has successfully initiated the Phase 3 MIRACLE trial for its drug Annamycin, which is a significant milestone. This trial is crucial as it evaluates Annamycin in combination with cytarabine for patients with relapsed or refractory acute myeloid leukemia (AML), and the interim data expected in the second half of 2025 could be a key value driver for the company.
Moreover, the prior Phase 2 trial showed promising results with a complete response rate of 50% for Annamycin, suggesting potential efficacy in the current trial setting. The management’s ability to secure funding and progress the trial despite challenging conditions further supports the positive outlook. Additionally, the approval of ‘naxtarubicin’ as the generic name for Annamycin by the World Health Organization is a step forward in the drug’s commercialization process, adding to the company’s potential for future success.

According to TipRanks, McCarthy is an analyst with an average return of -21.7% and a 26.41% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Medicus Pharma Ltd, and SELLAS Life Sciences Group.

In another report released on April 30, Roth MKM also maintained a Buy rating on the stock with a $20.00 price target.